BACKGROUND: Although most patients with classical Hodgkin's lymphoma (cHL) have a long survival duration, the current risk stratification is imperfect. A recent study suggested a prognostic role for the peripheral blood absolute lymphocyte count/absolute monocyte count (ALC/AMC) ratio at diagnosis in cHL. It is intriguing to investigate the significance of the ALC/AMC ratio in relation to tumor-associated macrophages (TAMs), yet another prognostic factor for cHL. METHODS: We examined the prognostic impact of the ALC, AMC, and ALC/AMC ratio in 312 cHL patients (median age, 37 years) using receiver operating characteristic curve analysis for optimal cutoff values, and compared these with TAM content. RESULTS: The median follow-up was 65 months (range, 0.1-245 months). On univariate analysis, a low ALC/AMC ratio (<2.9) was correlated with a poorer overall survival (OS) outcome. A subgroup analysis of patients with limited-stage disease showed that the ALC/AMC ratio was significantly correlated with the OS time. Multivariate analysis showed the ALC/AMC ratio to be an independent prognostic factor for OS outcome. A Spearman correlation test of TAM content showed a negative correlation with the ALC/AMC ratio and a positive correlation with the peripheral blood macrophage percentage. CONCLUSIONS: This study suggests that the ALC/AMC ratio may be a simple, inexpensive, and independent prognostic factor for OS outcome in patients with cHL and may have a role in the stratification of cHL patients in addition to the International Prognostic Score and TAM content.
BACKGROUND: Although most patients with classical Hodgkin's lymphoma (cHL) have a long survival duration, the current risk stratification is imperfect. A recent study suggested a prognostic role for the peripheral blood absolute lymphocyte count/absolute monocyte count (ALC/AMC) ratio at diagnosis in cHL. It is intriguing to investigate the significance of the ALC/AMC ratio in relation to tumor-associated macrophages (TAMs), yet another prognostic factor for cHL. METHODS: We examined the prognostic impact of the ALC, AMC, and ALC/AMC ratio in 312 cHL patients (median age, 37 years) using receiver operating characteristic curve analysis for optimal cutoff values, and compared these with TAM content. RESULTS: The median follow-up was 65 months (range, 0.1-245 months). On univariate analysis, a low ALC/AMC ratio (<2.9) was correlated with a poorer overall survival (OS) outcome. A subgroup analysis of patients with limited-stage disease showed that the ALC/AMC ratio was significantly correlated with the OS time. Multivariate analysis showed the ALC/AMC ratio to be an independent prognostic factor for OS outcome. A Spearman correlation test of TAM content showed a negative correlation with the ALC/AMC ratio and a positive correlation with the peripheral blood macrophage percentage. CONCLUSIONS: This study suggests that the ALC/AMC ratio may be a simple, inexpensive, and independent prognostic factor for OS outcome in patients with cHL and may have a role in the stratification of cHL patients in addition to the International Prognostic Score and TAM content.
Authors: T J Wijlhuizen; L W Vrints; R Jairam; W P Breed; J T Wijnen; L J Bosch; M A Crommelin; F E van Dam; J de Koning; M Verhagen-Teulings Journal: Cancer Date: 1989-03-15 Impact factor: 6.860
Authors: H Oh; H Takagi; C Takagi; K Suzuma; A Otani; K Ishida; M Matsumura; Y Ogura; Y Honda Journal: Invest Ophthalmol Vis Sci Date: 1999-08 Impact factor: 4.799
Authors: Douglas G McNeel; Thomas A Gardner; Celestia S Higano; Philip W Kantoff; Eric J Small; Mark H Wener; Robert B Sims; Todd DeVries; Nadeem A Sheikh; Robert Dreicer Journal: Cancer Immunol Res Date: 2014-09-04 Impact factor: 11.151
Authors: Zsofia Simon; S Barna; Z Miltenyi; K Husi; F Magyari; A Jona; I Garai; Z Nagy; G Ujj; L Szerafin; A Illes Journal: Int J Hematol Date: 2016-01 Impact factor: 2.490